JP2014532626A - 自然免疫応答を増強する化合物および方法 - Google Patents

自然免疫応答を増強する化合物および方法 Download PDF

Info

Publication number
JP2014532626A
JP2014532626A JP2014537274A JP2014537274A JP2014532626A JP 2014532626 A JP2014532626 A JP 2014532626A JP 2014537274 A JP2014537274 A JP 2014537274A JP 2014537274 A JP2014537274 A JP 2014537274A JP 2014532626 A JP2014532626 A JP 2014532626A
Authority
JP
Japan
Prior art keywords
group
trifluoromethyl
hydrogen
imidazo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014537274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532626A5 (https=
Inventor
バンカ，アンナ，リンゼイ
ボチャンスキー，ジャノス
バロウズ，エリック，グレゴリー
カタラーノ，ジョン，ジョージ
チャーン，ウェンディ，ファン
ディクソン，ハミルトン，ディー．
ガートランド，マーガレット，ジェイ．
ハマタケ，ロバート
ホフランド，ハンス
ケイチャー，ジェシー，ダニエル
ムーア，クリストファー，ブルックス
ショットウェル，ジョン，ブラッドフォード
タラント，マシュー，デヴィッド
テリーン，ジャン−フィリップ
ヨウ，シーユン
Original Assignee
グラクソスミスクライン エルエルシー
グラクソスミスクライン エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン エルエルシー, グラクソスミスクライン エルエルシー filed Critical グラクソスミスクライン エルエルシー
Publication of JP2014532626A publication Critical patent/JP2014532626A/ja
Publication of JP2014532626A5 publication Critical patent/JP2014532626A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2014537274A 2011-10-21 2012-10-19 自然免疫応答を増強する化合物および方法 Pending JP2014532626A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161549784P 2011-10-21 2011-10-21
US61/549,784 2011-10-21
US201261692431P 2012-08-23 2012-08-23
US61/692,431 2012-08-23
PCT/US2012/060971 WO2013059559A2 (en) 2011-10-21 2012-10-19 Compounds and methods for enhancing innate immune responses

Publications (2)

Publication Number Publication Date
JP2014532626A true JP2014532626A (ja) 2014-12-08
JP2014532626A5 JP2014532626A5 (https=) 2015-12-03

Family

ID=48141628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014537274A Pending JP2014532626A (ja) 2011-10-21 2012-10-19 自然免疫応答を増強する化合物および方法

Country Status (23)

Country Link
US (1) US20140249143A1 (https=)
EP (1) EP2768506A4 (https=)
JP (1) JP2014532626A (https=)
KR (1) KR20140094559A (https=)
CN (1) CN103957910A (https=)
AR (1) AR088793A1 (https=)
AU (1) AU2012325971B2 (https=)
BR (1) BR112014008727A2 (https=)
CA (1) CA2851801A1 (https=)
CL (1) CL2014001016A1 (https=)
CO (1) CO6910198A2 (https=)
CR (1) CR20140175A (https=)
DO (1) DOP2014000081A (https=)
EA (1) EA201490610A1 (https=)
IL (1) IL231894A0 (https=)
MX (1) MX2014004814A (https=)
PE (1) PE20141359A1 (https=)
PH (1) PH12014500865A1 (https=)
SG (2) SG10201505664WA (https=)
TW (2) TW201542567A (https=)
UY (1) UY34406A (https=)
WO (1) WO2013059559A2 (https=)
ZA (1) ZA201402392B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018043747A1 (ja) * 2016-09-05 2018-03-08 国立大学法人京都大学 抗ｂ型肝炎ウイルス剤
JP2023539896A (ja) * 2020-09-03 2023-09-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｓａｒｓ－ｃｏｖ－２感染を治療するためのｉｆｎａｒ２アゴニストとしてのイミダゾナフチリジンおよびイミダゾピリドピリミジン
WO2025089372A1 (ja) * 2023-10-26 2025-05-01 国立研究開発法人理化学研究所 イソインドリン誘導体

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
US10112895B2 (en) 2014-09-29 2018-10-30 The Trustees Of The University Of Pennsylvania Antivirals against molluscum contagiosum virus
CN104529893B (zh) * 2014-12-30 2016-08-24 中国科学技术大学 一类可以作为高尔基体细胞器探针的喹啉染料
CN105175277B (zh) * 2015-05-18 2018-04-03 中山大学肿瘤防治中心 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用
EP3601286A4 (en) 2017-03-28 2020-09-23 Pimera, Inc. NEW CRYSTALLINE FORMS OF A POL1 INHIBITOR
WO2020083662A1 (en) 2018-10-23 2020-04-30 Basf Se Tricyclic pesticidal compounds
CN114681472B (zh) * 2019-03-13 2023-06-30 中国人民解放军军事科学院军事医学研究院 氨基葡萄糖及其衍生物作为抗病毒药物的应用
EP4136086A1 (en) 2020-04-14 2023-02-22 Basf Se Tricyclic pesticidal compounds
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
CA3234375A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
WO2023244672A1 (en) 2022-06-14 2023-12-21 Assembly Biosciences, Inc. 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections
EP4694881A1 (en) * 2023-04-14 2026-02-18 Humanwell Pharmaceutical US, Inc. Monoacylglycerol lipase (magl) inhibitors for the treatment of pain and related medical disorders
WO2025128898A1 (en) 2023-12-13 2025-06-19 Assembly Biosciences, Inc. Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections
WO2026084955A1 (en) 2024-10-14 2026-04-23 Assembly Biosciences, Inc. Tricyclic heteroaryl compounds useful for enhancing innate immune responses
WO2026084957A1 (en) 2024-10-14 2026-04-23 Assembly Biosciences, Inc. Tricyclic heteroaryl compounds useful for enhancing innate immune responses
WO2026084958A1 (en) 2024-10-14 2026-04-23 Assembly Biosciences, Inc. Tricyclic heteroaryl compounds useful for enhancing innate immune responses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55105683A (en) * 1979-02-09 1980-08-13 Roussel Uclaf Novel heterotricyclic derivatives*their manufacture*their use as drug and pharmaceutic composition containing them
US4492697A (en) * 1983-08-16 1985-01-08 Ayerst, Mckenna & Harrison, Inc. 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives
WO2011054843A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Bromodomain inhibitors for treating autoimmune and inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2006503802A (ja) * 2002-04-03 2006-02-02 エフ．ホフマン−ラ　ロシュ　アーゲー イミダゾ縮合化合物
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
EP2416488B1 (en) * 2009-03-31 2019-03-06 Daikin Industries, Ltd. Electrode film for polymer actuator element, and polymer actuator element comprising same
GB201002409D0 (en) * 2010-02-12 2010-03-31 Univ Nottingham Methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55105683A (en) * 1979-02-09 1980-08-13 Roussel Uclaf Novel heterotricyclic derivatives*their manufacture*their use as drug and pharmaceutic composition containing them
US4492697A (en) * 1983-08-16 1985-01-08 Ayerst, Mckenna & Harrison, Inc. 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives
WO2011054843A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Bromodomain inhibitors for treating autoimmune and inflammatory diseases

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CASE, FRANCIS H.: "Preparation of 2-substituted benzimidazole derivatives containing the ferroin group", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 4(1), JPN6016019874, 1967, pages 157 - 159, ISSN: 0003326268 *
CASE, FRANCIS H.: "Preparation of Triazines and Benzimidazoles From 1- and 3-Cyanoisoquinolines(1)", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 4(4), JPN6016019876, 1967, pages 483 - 485, ISSN: 0003326269 *
DATABASE REGISTRY（STN）, JPN7016001336, 1986, ISSN: 0003326271 *
DATABASE REGISTRY, JPN7016001333, 2004, ISSN: 0003326264 *
DATABASE REGISTRY, JPN7016001334, 1987, ISSN: 0003326266 *
DATABASE REGISTRY, JPN7016001335, 1984, ISSN: 0003326270 *
NONAMI, HIROSHI 他: "Evaluation of pyridoindoles, pyridylindoles and pyridylpyridoindoles as matrices for ultraviolet mat", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 15(23), JPN6016019869, 2001, pages 2354 - 2373, ISSN: 0003326265 *
ROBINSON, R.; STEPHEN, A. M.: "Synthesis of vomipyrine", NATURE (LONDON, UNITED KINGDOM), vol. 162, JPN6016019873, 1948, pages 177 - 178, ISSN: 0003326267 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018043747A1 (ja) * 2016-09-05 2018-03-08 国立大学法人京都大学 抗ｂ型肝炎ウイルス剤
JP2023539896A (ja) * 2020-09-03 2023-09-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｓａｒｓ－ｃｏｖ－２感染を治療するためのｉｆｎａｒ２アゴニストとしてのイミダゾナフチリジンおよびイミダゾピリドピリミジン
WO2025089372A1 (ja) * 2023-10-26 2025-05-01 国立研究開発法人理化学研究所 イソインドリン誘導体

Also Published As

Publication number Publication date
CR20140175A (es) 2014-06-03
SG10201505664WA (en) 2015-09-29
PE20141359A1 (es) 2014-10-13
EA201490610A1 (ru) 2014-09-30
TW201333003A (zh) 2013-08-16
PH12014500865A1 (en) 2014-05-26
WO2013059559A3 (en) 2013-11-14
MX2014004814A (es) 2014-05-27
TW201542567A (zh) 2015-11-16
AU2012325971A1 (en) 2014-04-17
CN103957910A (zh) 2014-07-30
BR112014008727A2 (pt) 2017-04-25
US20140249143A1 (en) 2014-09-04
SG11201400988SA (en) 2014-07-30
DOP2014000081A (es) 2014-07-15
CA2851801A1 (en) 2013-04-25
EP2768506A2 (en) 2014-08-27
ZA201402392B (en) 2017-09-27
KR20140094559A (ko) 2014-07-30
AR088793A1 (es) 2014-07-10
UY34406A (es) 2013-05-31
IL231894A0 (en) 2014-05-28
AU2012325971B2 (en) 2016-03-31
CO6910198A2 (es) 2014-03-31
CL2014001016A1 (es) 2015-01-16
EP2768506A4 (en) 2015-08-19
WO2013059559A2 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
JP2014532626A (ja) 自然免疫応答を増強する化合物および方法
JP5882329B2 (ja) ＤＮＡ−ＰＫ阻害剤としてのイミダゾ［４，５−ｃ］キノリン
KR102827788B1 (ko) 인터페론 유전자 자극인자 sting의 효능제
TWI721016B (zh) B型肝炎核心蛋白質調節劑
AU2011258465B2 (en) Bicyclic heteroaryl kinase inhibitors and methods of use
JP5873544B2 (ja) Ｍｌｋ阻害剤および使用方法
KR101921764B1 (ko) 피라졸로-퀴놀린
JP2007518720A (ja) イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス治療の方法
CN110563722A (zh) 吡啶或哒嗪并环化合物及其应用
KR20220051226A (ko) 아자헤테로아릴 화합물 및 이의 용도
CN110117285B (zh) 流感病毒复制抑制剂及其用途
KR20220132592A (ko) 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
TW500724B (en) Oxazinoquinolones useful for the treatment of viral infections
JP2024521900A (ja) メチオニンアデノシルトランスフェラーゼ２ａ阻害剤
KR20220132594A (ko) 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
WO2024039861A1 (en) 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
CN115003383A (zh) 干扰素基因刺激物sting的双环激动剂
KR102466750B1 (ko) 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물
WO2024217428A1 (zh) 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
WO2025128898A1 (en) Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections
WO2024217452A1 (zh) 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
WO2024217446A1 (zh) 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
WO2024217429A1 (zh) 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
HK40081368A (en) Monocyclic agonists of stimulator of interferon genes sting
HK1184782B (zh) 吡唑并喹啉类化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151016

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170117